Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Agenus Inc's Business Segments
Agenus Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
US
Total Revenue
$ 35
Countrys Reported
1
Revenue Share by Reportable Segment - FY
- US0%
- Non Cash Royalty Revenue Related to the Sale of Future Royalties0%
- Non Cash Royalty Revenue0%
- Pre Commercial Product Revenue31.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 68 | - |
| Non Cash Royalty Revenue Related to the Sale of Future Royalties | $ 57 | - |
| Non Cash Royalty Revenue | $ 57 | - |
Revenue Share by Country - FY
- US100%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 35 | 100% |
Revenue by Product & Service Category - FY
- Non Cash Royalty Revenue Related to the Sale of Future Royalties81.5%
- Non Cash Royalty Revenue81.5%
- Pre Commercial Product Revenue18.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Non Cash Royalty Revenue Related to the Sale of Future Royalties | $ 28 | 81.5% |
| Non Cash Royalty Revenue | $ 28 | 81.5% |
| Pre Commercial Product Revenue | $ 6 | 18.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- US0%
- Non Cash Royalty Revenue Related to the Sale of Future Royalties0%
- Non Cash Royalty Revenue0%
- Pre Commercial Product Revenue31.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 68 | - |
| Non Cash Royalty Revenue Related to the Sale of Future Royalties | $ 57 | - |
| Non Cash Royalty Revenue | $ 57 | - |
1 more segments available
Sign in to unlock the full Agenus Inc dataset.
Description of Agenus Inc
Agenus Inc., headquartered in Lexington, Massachusetts, is a biopharmaceutical company primarily focused on developing innovative immuno-oncology treatments. With a strong emphasis on antibody-based therapeutics, the company aims to harness the power of the immune system to combat cancer and other diseases.
Agenus was founded in 1994 by Garo Armen, Ph.D., and it has since grown into a well-established player in the field of immuno-oncology. The company's main objective is to develop immunotherapies that stimulate the body's own immune response against cancer cells, aiming to provide more effective and safer treatment options for patients.
One of Agenus' key strengths lies in its proprietary drug discovery and development platform, known as Retrocyte Display™. This technology enables the rapid identification and isolation of novel antibodies and antibody-drug conjugates (ADCs) with potential therapeutic applications. By leveraging this platform, Agenus has successfully developed a robust pipeline of product candidates targeting various types of cancers.
The company's lead program is its anti-PD-1 antibody called balstilimab, which is being evaluated in multiple clinical trials for the treatment of solid tumors, including cervical cancer and advanced cutaneous squamous cell carcinoma (CSCC). Agenus is also developing other checkpoint inhibitor antibodies, such as anti-CTLA-4 antibody zalifrelimab, which is being studied in combination therapy approaches to enhance anti-tumor immune responses.
In addition to its checkpoint inhibitors, Agenus has an array of novel immuno-oncology therapies in various stages of development. This includes its anti-CTLA-4 antibody, AGEN1181, which utilizes bispecific antibody technology to expand its therapeutic potential. The company is also exploring the use of antibody-drug conjugates (ADCs) and adoptive cell therapies.
Agenus has established strategic partnerships and collaborations with leading pharmaceutical companies, such as Merck KGaA, and academic institutions to advance its research and development efforts. These collaborations provide access to additional resources and expertise, enabling Agenus to accelerate its drug development programs.
Moreover, the company has a manufacturing facility in Berkeley, California, dedicated to the production of clinical-grade antibodies and biologics. This in-house manufacturing capability ensures a reliable and scalable supply of its drug candidates for clinical trials and potential commercialization.
Agenus is committed to expanding its presence in the immuno-oncology field and optimizing its product portfolio by advancing its pipeline candidates through clinical development and pursuing regulatory approvals. The company's overarching goal is to deliver innovative therapies that can transform the lives of cancer patients and improve outcomes in the fight against this devastating disease.
Agenus was founded in 1994 by Garo Armen, Ph.D., and it has since grown into a well-established player in the field of immuno-oncology. The company's main objective is to develop immunotherapies that stimulate the body's own immune response against cancer cells, aiming to provide more effective and safer treatment options for patients.
One of Agenus' key strengths lies in its proprietary drug discovery and development platform, known as Retrocyte Display™. This technology enables the rapid identification and isolation of novel antibodies and antibody-drug conjugates (ADCs) with potential therapeutic applications. By leveraging this platform, Agenus has successfully developed a robust pipeline of product candidates targeting various types of cancers.
The company's lead program is its anti-PD-1 antibody called balstilimab, which is being evaluated in multiple clinical trials for the treatment of solid tumors, including cervical cancer and advanced cutaneous squamous cell carcinoma (CSCC). Agenus is also developing other checkpoint inhibitor antibodies, such as anti-CTLA-4 antibody zalifrelimab, which is being studied in combination therapy approaches to enhance anti-tumor immune responses.
In addition to its checkpoint inhibitors, Agenus has an array of novel immuno-oncology therapies in various stages of development. This includes its anti-CTLA-4 antibody, AGEN1181, which utilizes bispecific antibody technology to expand its therapeutic potential. The company is also exploring the use of antibody-drug conjugates (ADCs) and adoptive cell therapies.
Agenus has established strategic partnerships and collaborations with leading pharmaceutical companies, such as Merck KGaA, and academic institutions to advance its research and development efforts. These collaborations provide access to additional resources and expertise, enabling Agenus to accelerate its drug development programs.
Moreover, the company has a manufacturing facility in Berkeley, California, dedicated to the production of clinical-grade antibodies and biologics. This in-house manufacturing capability ensures a reliable and scalable supply of its drug candidates for clinical trials and potential commercialization.
Agenus is committed to expanding its presence in the immuno-oncology field and optimizing its product portfolio by advancing its pipeline candidates through clinical development and pursuing regulatory approvals. The company's overarching goal is to deliver innovative therapies that can transform the lives of cancer patients and improve outcomes in the fight against this devastating disease.
Agenus Inc. is a biotechnology innovator specializing in the research, development, and commercialization of immunotherapies aimed at treating cancer and other serious diseases. The company operates through two primary segments: the Oncology segment and the Vaccine segment. Below is a comprehensive overview of these segments, including the products and services that Agenus provides.
1. Oncology Segment:
The Oncology segment is dedicated to discovering and developing therapies that leverage the immune system to fight cancer. Agenus focuses on several key therapeutic categories:
- Checkpoint Modulators:
Agenus develops a portfolio of checkpoint modulator therapies that target critical immune regulatory proteins, including:
- CTLA-4 Inhibitors: These therapies block the CTLA-4 pathway, which down-regulates immune responses. By inhibiting CTLA-4, these treatments promote T-cell activation and proliferation.
- PD-1/PD-L1 Inhibitors: The company’s therapies also interfere with the PD-1/PD-L1 interaction, leading to enhanced T-cell activity against tumors. This mechanism is pivotal in allowing the immune system to recognize cancer cells as targets.
- Antibody-Drug Conjugates (ADCs):
Agenus is focused on developing ADCs that consist of monoclonal antibodies linked to potent cytotoxic agents. Key features include:
- Targeted Delivery: ADCs provide precision targeting of cancer cells while sparing healthy tissues, which reduces off-target effects.
- Enhanced Efficacy: These therapies can deliver high doses of chemotherapy directly to the tumor site, improving treatment outcomes for patients with difficult-to-treat cancers.
- Bispecific Antibodies:
Agenus is working on bispecific antibodies, which are engineered to bind simultaneously to two distinct antigens. This dual-targeting approach allows for:
- Recruitment of Immune Cells: Bispecific antibodies can bring T-cells directly to cancer cells, enhancing the immune response and leading to more effective tumor destruction.
- Combination Immunotherapies:
Understanding that cancer treatment often requires multiple strategies, Agenus emphasizes the development of combination therapies that can yield superior efficacy by:
- Utilizing Multiple Mechanisms: By combining different types of immunotherapies (e.g. checkpoint inhibitors with ADCs), the company aims to create synergistic effects that improve patient outcomes and increase the duration of response in tumors.
Vaccine Segment:
The Vaccine segment encompasses developing innovative vaccines to prevent and treat cancer, as well as augmenting immune responses to infectious diseases. Key offerings include:
- Prophage:
Agenuss personalized cancer vaccine platform, Prophage, utilizes:
- Patient-Derived Antigens: This vaccine is tailored using an individual’s tumor tissue to create a tailored therapeutic approach that prompts the immune system to attack cancer cells specifically.
- Clinical Success: Prophage has achieved promising results in clinical trials, particularly for glioblastoma, which is one of the most aggressive forms of brain cancer.
- AutoSynVax:
A cutting-edge off-the-shelf cancer vaccine platform, AutoSynVax focuses on:
- Neoantigen Activation: This vaccine targets tumor-specific neoantigens, stimulating robust T-cell responses tailored to the specific mutations present in an individual’s tumor.
- Broad Applicability: The technology has the potential to be applied across various cancer types, making it versatile in oncology treatments.
- QS-21 Stimulon:
Agenus also develops QS-21 Stimulon, an innovative adjuvant that:
- Enhances Immune Response: This component improves the immunogenicity of vaccine formulations, leading to stronger and more durable immune responses not only in cancer but also against infectious diseases.
Additional Collaborations:
Agenus collaborates with numerous partners within the biopharmaceutical sector, engaging in research and development, clinical trials, manufacturing, and commercialization. These partnerships aim to expedite the development of groundbreaking immunotherapies, ensuring that innovative treatments reach patients efficiently. By working alongside academic institutions, biotechnology firms, and large pharmaceutical companies, Agenus enhances its ability to deliver effective cancer therapies.
Overall, Agenus Inc. is at the forefront of immunotherapy development, striving to make significant advancements in oncology and vaccine research that can profoundly influence patient care across a range of serious diseases.
1. Oncology Segment:
The Oncology segment is dedicated to discovering and developing therapies that leverage the immune system to fight cancer. Agenus focuses on several key therapeutic categories:
- Checkpoint Modulators:
Agenus develops a portfolio of checkpoint modulator therapies that target critical immune regulatory proteins, including:
- CTLA-4 Inhibitors: These therapies block the CTLA-4 pathway, which down-regulates immune responses. By inhibiting CTLA-4, these treatments promote T-cell activation and proliferation.
- PD-1/PD-L1 Inhibitors: The company’s therapies also interfere with the PD-1/PD-L1 interaction, leading to enhanced T-cell activity against tumors. This mechanism is pivotal in allowing the immune system to recognize cancer cells as targets.
- Antibody-Drug Conjugates (ADCs):
Agenus is focused on developing ADCs that consist of monoclonal antibodies linked to potent cytotoxic agents. Key features include:
- Targeted Delivery: ADCs provide precision targeting of cancer cells while sparing healthy tissues, which reduces off-target effects.
- Enhanced Efficacy: These therapies can deliver high doses of chemotherapy directly to the tumor site, improving treatment outcomes for patients with difficult-to-treat cancers.
- Bispecific Antibodies:
Agenus is working on bispecific antibodies, which are engineered to bind simultaneously to two distinct antigens. This dual-targeting approach allows for:
- Recruitment of Immune Cells: Bispecific antibodies can bring T-cells directly to cancer cells, enhancing the immune response and leading to more effective tumor destruction.
- Combination Immunotherapies:
Understanding that cancer treatment often requires multiple strategies, Agenus emphasizes the development of combination therapies that can yield superior efficacy by:
- Utilizing Multiple Mechanisms: By combining different types of immunotherapies (e.g. checkpoint inhibitors with ADCs), the company aims to create synergistic effects that improve patient outcomes and increase the duration of response in tumors.
Vaccine Segment:
The Vaccine segment encompasses developing innovative vaccines to prevent and treat cancer, as well as augmenting immune responses to infectious diseases. Key offerings include:
- Prophage:
Agenuss personalized cancer vaccine platform, Prophage, utilizes:
- Patient-Derived Antigens: This vaccine is tailored using an individual’s tumor tissue to create a tailored therapeutic approach that prompts the immune system to attack cancer cells specifically.
- Clinical Success: Prophage has achieved promising results in clinical trials, particularly for glioblastoma, which is one of the most aggressive forms of brain cancer.
- AutoSynVax:
A cutting-edge off-the-shelf cancer vaccine platform, AutoSynVax focuses on:
- Neoantigen Activation: This vaccine targets tumor-specific neoantigens, stimulating robust T-cell responses tailored to the specific mutations present in an individual’s tumor.
- Broad Applicability: The technology has the potential to be applied across various cancer types, making it versatile in oncology treatments.
- QS-21 Stimulon:
Agenus also develops QS-21 Stimulon, an innovative adjuvant that:
- Enhances Immune Response: This component improves the immunogenicity of vaccine formulations, leading to stronger and more durable immune responses not only in cancer but also against infectious diseases.
Additional Collaborations:
Agenus collaborates with numerous partners within the biopharmaceutical sector, engaging in research and development, clinical trials, manufacturing, and commercialization. These partnerships aim to expedite the development of groundbreaking immunotherapies, ensuring that innovative treatments reach patients efficiently. By working alongside academic institutions, biotechnology firms, and large pharmaceutical companies, Agenus enhances its ability to deliver effective cancer therapies.
Overall, Agenus Inc. is at the forefront of immunotherapy development, striving to make significant advancements in oncology and vaccine research that can profoundly influence patient care across a range of serious diseases.